Catalog No.
YHC28901
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Leu29-Arg635
Predicted molecular weight
70.09 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P07949
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
RET51, Proto-oncogene c-Ret, Cadherin family member 12, RET, Proto-oncogene tyrosine-protein kinase receptor Ret, CDHF12, CDHR16, PTC
[Case Report: Histological Transformation to Atypical Carcinoid in RET Fusion-positive NSCLC Following Immune Therapy Resistance]., PMID:40506495
Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy., PMID:40496186
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer., PMID:40458063
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors., PMID:40405293
Efficacy and safety of RET-kinase inhibitors in RET-altered thyroid cancers: a systematic review and single-arm meta-analysis., PMID:40331677
Biology of RET receptor and its ligands: focus on the nervous system., PMID:40272927
Exploration of risk factors for the occurrence and recurrence of papillary thyroid carcinoma with Hashimoto's thyroiditis based on next-generation sequencing., PMID:40269951
Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing., PMID:40177881
Treatment of non-small cell lung cancer with RET rearrangements., PMID:40171987
[Lung cancers with rare oncogenic drivers: RET, ROS-1, MET, HER2 and BRAF]., PMID:40155071
Activation of DCTN1-RET Fusion Through Coiled-coil Domain as a Potential Target for RET Inhibitors., PMID:40155036
Genomic testing for RET in the clinic: UK and global perspective., PMID:40138217
Highly infiltrative brain metastasis of RET mutant lung primary: Morphometric assessment and molecular review., PMID:40116187
Treatment of RET/ALK comutated advanced lung large cell neuroendocrine carcinoma: a case report and literature review., PMID:40112204
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals., PMID:40102447
Systemic Therapies for Advanced Medullary Thyroid Carcinoma., PMID:40102263
Primary Hyperparathyroidism in MEN2 Syndromes., PMID:40102260
Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation., PMID:40102258
Epidemiology, Clinical Presentation, and Diagnosis of Medullary Thyroid Carcinoma., PMID:40102255
What Is New in Diagnostics and Management of Medullary Thyroid Carcinoma., PMID:40102252
Primary low-grade salivary gland-type intraductal carcinoma of the lung with CCDC6::RET fusion: Case presentation and literature review., PMID:40036626
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial., PMID:40016191
Variability in proliferative and migratory defects in Hirschsprung disease-associated RET pathogenic variants., PMID:40010351
Neurturin-induced activation of GFRA2-RET axis potentiates pancreatic cancer glycolysis via phosphorylated hexokinase 2., PMID:39988080
Clinical, Morphologic, and Genomic Findings in Spitz Tumors With RET Fusion: A Series of 31 Cases., PMID:39986469
Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial., PMID:39983053
Identification of Oncogenic Alterations in 124 Cases of Pediatric Papillary Thyroid Carcinoma: BEND7::ALK, DLG5::RET, and CCDC30::ROS1 Fusions Induce MAPK Pathway Activation., PMID:39982551
Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets., PMID:39950716
Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report., PMID:39907599
Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples., PMID:39887260
Design, synthesis and evaluation of (E)-1-(4-(2-(1H-pyrazol-5-yl)vinyl)phenyl) derivatives as next generation selective RET inhibitors overcoming RET solvent front mutations (G810C/R)., PMID:39879936
Proteomic Profiling of Medullary Thyroid Cancer Identifies CAPN1 as a Key Regulator of NF1 and RET Fueled Growth., PMID:39868924
Natural history of medullary thyroid carcinoma in MEN 2 patients carrying a variant at codon 804 in the RET proto-oncogene: A study by the French Neuroendocrine Tumor Group (GTE)., PMID:39842635
Rearranged during transfection (RET) lung cancer - Update on targeted therapies., PMID:39827484
Na+-concentration dependent conformational switch of oncogene RET G-quadruplex DNA in solution., PMID:39824413
Rare and common genetic variants underlying the risk of Hirschsprung's disease., PMID:39817569
Assessment of Exhaled Breath Condensate for ALK, RET, ROS1, and NTRK1 Fusion Transcript Detection in NSCLC: Comparison With Tissue and Liquid Biopsy Samples., PMID:39810398
Mechanisms of Adaptive Resistance to Targeted Therapy in RET-Aberrant Cancers., PMID:39808501
RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs., PMID:39800214
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model., PMID:39778760
Discovery of a Selective and Orally Bioavailable RET Degrader with Effectiveness in Various Mutations., PMID:39772547
[Characteristics of RET gene rearrangement detected by fluorescence in situ hybridization in lung cancer]., PMID:39762169
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy., PMID:39748713
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly., PMID:39745188
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations., PMID:39731581
Human Enteric Glia Diversity in Health and Disease: New Avenues for the Treatment of Hirschsprung Disease., PMID:39725172
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein., PMID:39723919
A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer., PMID:39716145
Acoustic-pressure-driven ultrasonic activation of the mechanosensitive receptor RET and of cell proliferation in colonic tissue., PMID:39706982
Dissection of RET p.M918T-driven progression of hereditary vs. sporadic medullary thyroid cancer., PMID:39705856
For research use only. Not for human or drug use.
